Dose Modification and Therapy Interruption Due to Adverse Events in Treatment with Anlotinib for Refractory Advanced NSCLC: Data from ALTER0303

L. Zhang,X. Si,H. Wang,X. Zhang,M. Wang,B. Han,K. Li,Q. Wang,J. Shi,Z. Wang,Y. Cheng,J. He,Y. Shi,W. Chen,X. Wang,Y. Luo,K. Nan,F. Jin,B. Li,Y. Chen

DOI: https://doi.org/10.1093/annonc/mdy292.013

IF: 51.769

2018-01-01

Annals of Oncology

Abstract:Background: Anlotinib is an oral tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR and c-kit. Anlotinib showed significantly improvement in overall survival in ALTER0303 trial for refractory NSCLC, a randomized, double-blind, placebo-controlled phase III trial in China. This study reported the tolerance of anlotinib in the ALTER0303. Methods: The adverse events (AEs), dose modification, and therapy interruption were collected from anlotinib group (n = 294) and placebo group (n = 143) that were enrolled in ALTER0303. AEs were graded using Common Terminology Criteria. Results: The anlotinb related grade ≥3 AEs reported in ≥ 1% patients were hypertension (13.3%), hyponatremia (4.8%), hand-foot syndrome (HFS) (3.7%), hemoptysis (3.1%), GGT elevation (2.7%), hypertriglyceridemia (2.4%), QT interval prolongation (2.4%), lipase elevation (2.4%), proteinuria (2.4%), oral mucositis (1.0%), diarrhea (1.0%), and hyperbilirubinemia (1.0%). Grade ≥3 hypertension, HFS, and hypertriglyceridemia were significantly more frequent in the anlotinib group than in the control group. Dose reduction and drug interruption were required in 24 (8.16%) (Table) and 31 (10.54%) patients in anlotinib group, respectively. The most common anlotinib-related AEs causing interruption were hemoptysis (2.3%), venous thromboembolism (1.0%), proteinuria (0.7%), interstitial lung disease (0.7%), and pneumothorax (0.7%).Table: 1390PDose modification due to anlotinib-related adverse eventsAdverse eventsNo. (%)Dose modificationHand-foot syndrome7 (2.3)12mg→10mgHypertension3 (1.0)12mg→10mgHypertriglyceridemia2 (<1)12mg→10mgDiarrhea1 (<1) 1 (<1)12mg→10mg 12mg→10mg→8mgLiver dysfunction1 (<1) 1 (<1)12mg→10mg 12mg→10mg→8mgAnorexia2 (<1)12mg→10mgOral mucositis2 (<1)12mg→10mgArrhythmia2 (<1)12mg→10mgFatigue1 (<1)12mg→10mgDyspnea1 (<1)12mg→10mg Open table in a new tab Conclusions: It was important to manage hand-foot syndrome, hypertension, diarrhea and hemoptysis, so that patients could benefit from anlotinib. Clinical trial identification: NCT02388919. Legal entity responsible for the study: Chia Tai Tianqing Pharmaceutical Group Co., LTD. Funding: Chia Tai Tianqing Pharmaceutical Group Co., LTD. Disclosure: All authors have declared no conflicts of interest.